---
document_datetime: 2025-09-11 10:39:46
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rukobia-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: rukobia-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3636077
conversion_datetime: 2025-12-27 09:19:15.757627
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rukobia

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                  | Scope                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                              |
|-------------------------------------|-----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 5 year / EMA/R/0000264656 | - Renewal - Renewal of marketing authorisation with | 24/07/2025                          | 08/09/2025                                  | SmPC, Annex II and PL            | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Rukobia in the approved indication |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | unlimited validity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     | remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                            |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000253073 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z (IB) - To provide a revised RMP version to update the final study report milestone of \"A Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir in HTE Subjects Infected with Multi-drug Resistant HIV-1 (BRIGHTE Study)\" from 31 December 2025 to 31 December 2026. | 31/03/2025 | N/A | To provide a revised RMP version to update the final study report milestone of \"A Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir in HTE Subjects Infected with Multi-drug Resistant HIV-1 (BRIGHTE Study)\" from 31 December 2025 to 31 December 2026. |
| Variation type IB / EMA/VR/0000244295 | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 28/03/2025 | N/A |                                                                                                                                                                                                                                                                             |